The Importance of TIMI 3 flow in primary angioplasty

Original title: Predicitors of suboptimal TIMI flow alter primary angioplasty for acute myocardial infarction: results from the HORIZON-AMI trial. Reference: Adriano Caixeta et al.  Eurointervention 2013;9:220-227

Primary angioplasty showed greater efficacy than thrombolytics but one out of every four patients cannot achieve TIMI 3 flow.

The Horizons-AMI trial randomized 3,602 patients to receive bivalirudin or heparin plus inhibitors IIb IIIa and after angiography a second randomization took place to DES or a conventional stent. The primary objective of this analysis was to evaluate the angiographic predictors of both clinical and suboptimal procedural flow (TIMI <3) after stent implantation. The secondary objective was the impact after three years of suboptimal flow, (TIMI 0-2 versus TIMI 3). Angioplasty was performed in 3,345 patients, (92.9%), of which 2,758, (87.1%), had final TIMI 3 flow.

Those who had TIMI

After 30 days and three years, end TIMI flow

Conclusion:

In this large study the lack of restoration of TIMI 3 flow was associated with older age, past infarction, TIMI flow 0-1, lesion length and was a strong predictor of mortality.

Commentary:

This study shows that the failure to achieve TIMI 3 is associated with higher mortality at three years, than the PAMI, Cadillac and Apex IMA studies had shown at six months. It may be important to have a good pre-hospital service where trained personnel are available to bypass the emergency department and refer the patient directly to the catheterization laboratory. 

Courtesy of Dr Carlos Fava.
Interventional Cardiologist.
Favaloro Foundation.
Buenos Aires, Argentina.

Dr. Carlos Fava para SOLACI.ORG

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....